Aurora Cannabis Inc. has appointed Faris El Refaie, a biopharmaceutical executive with 25 years of experience, as Executive Vice President, Global Commercial, effective September 28, 2026. In the newly created role, he will oversee Aurora's global commercial function and help advance its medical cannabis market strategy, align its international portfolio, increase customer engagement and accelerate commercial capabilities across Canada, Europe, Australia, New Zealand and other markets. El Refaie previously held leadership positions at JAMP Pharma Group, GSK and AstraZeneca, with experience spanning innovative medicines, oncology, specialty care, vaccines and consumer healthcare. Aurora said the appointment supports its expansion across established and emerging international medical cannabis markets. The company operates medical cannabis businesses across Canada, Europe, Australia and New Zealand, with GMP-certified manufacturing facilities in Canada and Germany. Its common shares trade on the NASDAQ and TSX under the symbol ACB. Aurora's release also contains forward-looking information about commercial acceleration and future growth, subject to financial, market, regulatory and operational risks.